Viking to price its IPO of 5 million shares between $10.00 and $12.00

Oppenheimer, Roth Capital Partners to be bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., Sept. 16 – Viking Therapeutics, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe option of 750,000 additional shares, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The deal was announced July 1.

The shares will be sold at a price expected to fall between $10.00 and $12.00 per share.

Oppenheimer & Co. and Roth Capital Partners are the joint bookrunning managers. Craig-Hallum Capital Group is the lead manager and MLV & Co. and Summer Street Research Partners are the co-managers.

Ligand Pharmaceuticals Inc. intends to buy about $5 million of shares at the initial public offering price.

Proceeds will be used for clinical development, working capital and other general corporate purposes.

The biopharmaceutical company is based in San Diego. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “VKTX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.